Portal de investigación
Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Venditti, Adriano
- Hou, Jing-Zhou
- Fenaux, Pierre
- Jonas, Brian A.
- Vrhovac, Radovan
- Garcia, Jacqueline S.
- Rizzieri, David
- Thirman, Michael J.
- Montez, Melissa
- Liu, Yingyi
- Katsetos, John
- Potluri, Jalaja
- Miller, Catherine
- Pullarkat, Vinod A.
Grupos
Abstract
Abstract no disponible
Datos de la publicación
- ISSN/ISSNe:
- 0006-4971, 1528-0020
- Tipo:
- Meeting Abstract
- Páginas:
- 8993-8995
- Factor de Impacto:
- 4,834 SCImago ℠
- Cuartil:
- Q1 SCImago ℠
BLOOD ELSEVIER
Documentos
- No hay documentos
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Venditti,A,Hou,J,Fenaux,P,Jonas,BA,Vrhovac,R,Montesinos,P,Garcia,JS et al. Application of a Validated Composite Comorbidity Score Measuring Both Fitness and Cytogenetic Risk to Assess Outcomes in 1L AML Patients Who Received Venetoclax Plus Azacitidine in Viale-A. 64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). 2022. New Orleans-LA. RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS:ELSEVIER. 2022 p.p. 8993-8995.